Anti-MSH2 antibody-conjugated liposomes have shown great potential in ovarian cancer research. Firstly, they can specifically target tumor cells that express MSH2, thereby increasing the selectivity and efficacy of the treatment. Secondly, these liposomes can effectively carry anticancer drugs, enhancing drug uptake and bioavailability in cells. Finally, by improving drug distribution and reducing side effects, anti-MSH2 antibody-conjugated liposomes are expected to become a new strategy for the treatment of ovarian cancer.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2297 | Hi-Affi™ Recombinant Rabbit Anti-MSH2 Monoclonal Antibody (DS2297AB) | FC, ICC/IF, IHC-P, WB | IgG |
There are currently no Customer reviews or questions for VS-1024-FY216. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.